Literature DB >> 6312680

Deletion mutants of region E1a of AD12 E1 plasmids: effect on oncogenic transformation.

J L Bos, A G Jochemsen, R Bernards, P I Schrier, H van Ormondt, A J van der Eb.   

Abstract

Plasmids containing the E1 region of Ad12 DNA can transform certain rodent cells into oncogenic cells. To study the role of the E1a subregion in the process of oncogenic transformation, Ad12 region E1 mutants carrying deletions in the E1a region were constructed. Deletion mutants pR7 and pR8 affect only the 13 S mRNA species encoded by region E1a, whereas deletion mutants pR11 and pR15 damage both the 12 S and 13 S E1a mRNA. All four mutants have lost their capacity to transform primary cultures of baby rat kidney cells, indicating that the E1a gene product encoded by 13 S mRNA is essential for transformation. It was further found that the mutated E1a regions of both pR7 and pR11 can induce expression of region E1b, which implies that the transformation deficiency of these mutants is not due to the inability to activate E1b expression. Surprisingly, the transforming capacity of pR7 and pR11 is restored when these mutant E1 regions are covalently coupled to the SV40 "enhancer" region. Cells transformed by these hybrids plasmids, however, were not tumorigenic in nude mice.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6312680     DOI: 10.1016/0042-6822(83)90178-2

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  16 in total

1.  Evidence that a second tumor antigen coded by adenovirus early gene region E1a is required for efficient cell transformation.

Authors:  D R Hurwitz; G Chinnadurai
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

2.  Mapping of functional domains in adenovirus E1A proteins.

Authors:  B Krippl; B Ferguson; N Jones; M Rosenberg; H Westphal
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

Review 3.  p53 gene in treatment of hepatic carcinoma: status quo.

Authors:  Yong-Song Guan; Zi La; Lin Yang; Qing He; Ping Li
Journal:  World J Gastroenterol       Date:  2007-02-21       Impact factor: 5.742

4.  Transformation properties of type 5 adenovirus mutants that differentially express the E1A gene products.

Authors:  K P Haley; J Overhauser; L E Babiss; H S Ginsberg; N C Jones
Journal:  Proc Natl Acad Sci U S A       Date:  1984-09       Impact factor: 11.205

5.  Early region 1 transforming functions are dispensable for mammary tumorigenesis by human adenovirus type 9.

Authors:  D L Thomas; S Shin; B H Jiang; H Vogel; M A Ross; M Kaplitt; T E Shenk; R T Javier
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

6.  Synthesis in Escherichia coli of human adenovirus type 12 transforming proteins encoded by early region 1A 13S mRNA and 12S mRNA.

Authors:  D Kimelman; L A Lucher; K H Brackmann; J S Symington; M Ptashne; M Green
Journal:  Proc Natl Acad Sci U S A       Date:  1984-10       Impact factor: 11.205

7.  Oncogenicity by adenovirus is not determined by the transforming region only.

Authors:  R Bernards; M G de Leeuw; M J Vaessen; A Houweling; A J van der Eb
Journal:  J Virol       Date:  1984-06       Impact factor: 5.103

8.  Different activities of the adenovirus types 5 and 12 E1A regions in transformation with the EJ Ha-ras oncogene.

Authors:  A G Jochemsen; R Bernards; H J van Kranen; A Houweling; J L Bos; A J van der Eb
Journal:  J Virol       Date:  1986-09       Impact factor: 5.103

9.  A first exon-encoded domain of E1A sufficient for posttranslational modification, nuclear-localization, and induction of adenovirus E3 promoter expression in Xenopus oocytes.

Authors:  J D Richter; P Young; N C Jones; B Krippl; M Rosenberg; B Ferguson
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

10.  Posttranslational modification at the N terminus of the human adenovirus type 12 E1A 235R tumor antigen.

Authors:  L A Lucher; K H Brackmann; J S Symington; M Green
Journal:  J Virol       Date:  1986-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.